CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

COVID-19 convalescent plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1267 Standard (specific) therapy for COVID-19 Wiki 0.58
drug85 Anti-COVID-19 human immunoglobulin Wiki 0.58

Correlated MeSH Terms (11)

Name (Synonyms) Correlation
D001167 Arteritis NIH 0.41
D025241 Spondylarthritis NIH 0.41
D011111 Polymyalgia Rheumatica NIH 0.41
D013700 Giant Cell Arteritis NIH 0.41
D012859 Sjogren's Syndrome NIH 0.41
D001327 Autoimmune Diseases NIH 0.33
D008180 Lupus Erythematosus, Systemic NIH 0.29
D001172 Arthritis, Rheumatoid NIH 0.29
D001168 Arthritis NIH 0.19
D018352 Coronavirus Infections NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.03

Correlated HPO Terms (5)

Name (Synonyms) Correlation
HP:0012089 Arteritis HPO 0.41
HP:0002960 Autoimmunity HPO 0.33
HP:0001370 Rheumatoid arthritis HPO 0.33
HP:0002725 Systemic lupus erythematosus HPO 0.29
HP:0001369 Arthritis HPO 0.22

There are 3 clinical trials

Clinical Trials

1 Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

NCT04338360 COVID19 Biological: COVID-19 convalescent plasma

2 Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial

Currently there is no standard treatment for SARS-CoV-2 infection. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including SARS-CoV-1 , MERS-CoV and Hantavirus infection. This study is an open-label randomized trial in which patients with high risk of COVID19-associated respiratory failure will be randomized to early treatment with convalescent plasma (< 7 days from symptoms start) or at early signs of respiratory failure or prolonged hospitalization. COVID-19 convalescent plasma will be collected from individuals according to the institutional protocol.

NCT04375098 Severe Acute Respiratory Syndrome Coronavirus 2 Biological: COVID-19 convalescent plasma
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Measure: Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization

Time: 1 year follow up

Secondary Outcomes

Description: Days

Measure: Median duration of fever

Time: 1 year

Description: Days

Measure: Median duration of mechanical ventilation

Time: 1 year follow up

Description: Days

Measure: Median length of ICU stay

Time: 1 year follow up

Description: Days

Measure: Median length of admission

Time: 1 year follow up

Measure: Hospital mortality rate (percentage)

Time: 1 year follow up

Measure: 30-day mortality (percentage)

Time: 1 year follow up

Measure: Readmission rate (percentage)

Time: 1 year follow up

Description: days

Measure: Median length of viral clearance

Time: 1 year follow up

3 A Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment in Hospitalized Patients

A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.

NCT04395170 Coronavirus Disease 2019 (COVID-19) Biological: COVID-19 convalescent plasma Biological: Anti-COVID-19 human immunoglobulin Drug: Standard (specific) therapy for COVID-19
MeSH:Coronavirus Infections

Primary Outcomes

Description: Admission to the intensive care unit with the requirement of mechanical ventilation (invasive or non-invasive) due to Acute Respiratory Distress Syndrome by COVID-19.

Measure: Admission to ICU and/or mechanical ventilation

Time: One year

Secondary Outcomes

Description: Time in the hospital from admission to discharge or death.

Measure: Length of hospital stay

Time: One year

Description: Neutralizing antibody (IgG) titers against COVID-19

Measure: Neutralizing antibody (IgG) titers against COVID-19

Time: One year

Description: Non-serious adverse events (NSAEs) and serious adverse events (SAEs)

Measure: Safety - Adverse events

Time: One year

Description: Overall mortality

Measure: Death

Time: One year

No related HPO nodes (Using clinical trials)